Landmark trials in aspirin prophylaxis
Review the foundational research and clinical trials that established low-dose aspirin as the standard for preventing preeclampsia and preterm birth.
Foundational Aspirin Research
"Initial large-scale investigations into low-dose aspirin for high-risk pregnancy outcomes."
The Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) established the safety profile of aspirin, setting the stage for targeted prophylaxis in patients with high-risk clinical profiles.
Optimizing Dosage & Timing
"Systematic reviews confirming that initiation before 16 weeks gestation maximizes placental benefit."
Research shifted toward timing and dosage, identifying that early initiation is critical for proper spiral artery remodeling and reducing the incidence of preterm preeclampsia.
Evidence-Based Implementation
"ASPRE trial results demonstrating significant reduction in preterm preeclampsia with 150mg daily."
Contemporary guidelines now mandate universal screening and prophylactic aspirin for high-risk patients, integrating trial data into standard obstetric care to prevent maternal-fetal morbidity.
Evidence-based clinical practice
These trials form the basis of current obstetric guidelines, ensuring that prophylactic aspirin is administered safely and effectively to those at risk.
Evidence-Based Safety and Maternal Outcomes
Rigorous clinical appraisal of low-dose aspirin prophylaxis, focusing on maternal safety, fetal development, and long-term obstetric health.
Clinical data confirms that low-dose aspirin does not increase the risk of placental abruption or postpartum hemorrhage in high-risk cohorts.
- Meta-analysis of 30,000+ pregnancies
- No significant rise in hemorrhage
- Safe for standard obstetric care
Extensive longitudinal studies demonstrate no association between low-dose aspirin and fetal intracranial bleeding or congenital malformations.
- No link to congenital defects
- Normal neurodevelopmental scores
- Safe for fetal vascular health
Current guidelines support 81-150mg daily. This dosage effectively inhibits thromboxane A2 while sparing essential endothelial prostacyclin.
- Initiate before 16 weeks gestation
- Evening administration preferred
- Evidence-based titration protocols
Prophylaxis significantly lowers the incidence of early-onset preeclampsia, directly improving maternal and neonatal survival rates.
- Prevents early-onset preeclampsia
- Reduces iatrogenic preterm birth
- Improves uterine artery perfusion
Review Full Clinical Guidelines
Access the complete ACOG and USPSTF committee opinions regarding prophylactic aspirin use in pregnancy.